5 Stocks Insiders Are Selling
When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to go short on the stock. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision.
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength.
Where Moderna Stands With Analysts
Analysts have provided the following ratings for Moderna (NASDAQ:MRNA) within the last quarter:
Why Moderna Shares Are Falling
Moderna Inc (NASDAQ: MRNA) shares are trading lower after Deutsche Bank initiated coverage on the stock with a Sell rating and a $250 price target.
Johnson & Johnson’s Shot Success Overshadowed by Baby Powder Cancer Suit
On Tuesday, Johnson & Johnson (NYSE: JNJ) exceeded Wall Street's profit expectations but revenue missed forecasts for its third quarter.
The Daily Biotech Pulse: Athira CEO Resigns Over Doctored Research, Merck’s Keytruda Snags First Approval For Breast Cancer In Europe, Minerva And Xilio IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Deutsche Bank Initiates Coverage On Moderna with Sell Rating, Announces Price Target of $250
Deutsche Bank initiates coverage on Moderna (NASDAQ:MRNA) with a Sell rating and announces Price Target of $250.